Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOGF), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alpha Cognition's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alpha Cognition's position in the market.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) has appointed Dr. Cedric O’Gorman as Chief Medical Officer. With over 20 years in life sciences, Dr. O’Gorman will oversee medical, clinical, and regulatory functions for clinical-stage products ALPHA-1062 and ALPHA-0602. His previous roles include leadership positions at Axsome Therapeutics and Genentech, focusing primarily on CNS therapeutic areas. CEO Michael McFadden highlighted Dr. O’Gorman’s expertise as vital for advancing the company's clinical programs aimed at neurodegenerative diseases.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced its Q3-2021 financial results, reporting a net loss of $4.3M, or $(0.09) per share, up from a $1.5M loss in Q3-2020. Research and development expenses increased to $2.1M, while general and administrative expenses rose to $340k. The company ended the quarter with $5.6M in cash. Alpha Cognition is advancing clinical programs for ALPHA-1062 and ALPHA-0602, focusing on neurodegenerative disorders. CEO Michael McFadden stated the company is well-positioned with a $10.7M funding raise for R&D into 2022.
Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF) is set to present at the LD Micro Main Event on October 12th at 3:00 PM EST in location value="LU/us.ca.losang"Los Angeles. CEO Michael McFadden will discuss the company's innovative therapies targeting neurodegenerative disorders, specifically highlighting ALPHA-1062 and ALPHA-0602. This annual event, running from October 12th to October 14th, features around 150 presenting companies and aims to connect investors with emerging opportunities.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced a business update by CEO Michael McFadden, highlighting the company's strategic changes aimed at enhancing shareholder value and advancing its neurodegenerative drug pipeline. Key developments include a comprehensive review of their lead product, ALPHA-1062, targeting Alzheimer’s, with a market opportunity larger than anticipated. The company aims to commercialize ALPHA-1062 in the US Alzheimer market, worth $5B annually, and plans trials for both Alzheimer's and ALS products.
Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF) has announced the formation of a Scientific Advisory Board (SAB) to enhance its clinical development pipeline in neurological therapies. Chaired by James E. Galvin, MD, MPH, the SAB comprises experts from the fields of neurology and psychiatry, including Frank Conidi and Jeffrey Cummings. The SAB aims to provide strategic guidance for the company’s lead candidate, ALPHA-1062, which targets Alzheimer's disease. Additionally, Alpha Cognition has engaged Bello Capital Partners for investor relations efforts.
Alpha Cognition Inc. (ACOGF) has received FDA acceptance for its Investigational New Drug (IND) application for ALPHA-1062, aimed at treating mild to moderate Alzheimer’s Disease. This pivotal study will examine the bioavailability of ALPHA-1062, a delayed release oral tablet designed to improve tolerability over existing treatments. The company plans to initiate trials in Q3 2021, with potential New Drug Application submission in Q3 2022, should results be favorable. ALPHA-1062 may leverage existing approval pathways due to its metabolite being an already approved drug.
Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF) announced its Q2 2021 financial results, reporting a net loss of $1.8 million or $(0.04) per share. Research and development expenses were $1.5 million, while general and administrative expenses totaled $100,000. The company ended the quarter with $5.6 million in cash and cash equivalents. Alpha Cognition plans to initiate pivotal trials for ALPHA-1062 in Alzheimer's disease in Q3 2021, and an early-stage trial for ALPHA-0602 in ALS in Q4 2021, with data expected by Q1 2022.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually from September 13-15, 2021. CEO Michael McFadden will present details on the company's lead product, ALPHA-1062, designed for Alzheimer's treatment, which has shown promising safety in trials. Additionally, ALPHA-0602, aimed at neurodegenerative diseases, has received Orphan Drug Designation. The presentation will be available at 7:00 AM EST on September 13, 2021. One-on-one investor meetings will also be conducted.
Alpha Cognition Inc. (ACOGF) announced its common shares have been approved for quotation on the OTCQB Venture Market starting August 18, 2021. This move aims to enhance equity, liquidity, and visibility in the U.S. market while continuing to trade on the TSX Venture Exchange. Alpha Cognition is focused on developing therapies for neurodegenerative diseases, notably ALPHA-1062, which has shown safety in trials and aims to treat Alzheimer’s with minimal side effects. The company holds patents for its treatments, including one with Orphan Drug Designation.